Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2013

Open Access 01-12-2013 | Research article

An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate

Authors: Christopher Hautmann, Aribert Rothenberger, Manfred Döpfner

Published in: BMC Psychiatry | Issue 1/2013

Login to get access

Abstract

Background

Methylphenidate (MPH) has been shown to be effective in the treatment of attention deficit hyperactivity disorder (ADHD) in children. The overall population of children and adolescents with ADHD may comprise distinct clusters of patients that differ in response to MPH. The aim of this analysis was to look for subgroups with different treatment trajectories and to identify their distinctive features.

Methods

OBSEER was a prospective, observational study examining the effectiveness and safety of once-daily modified-release MPH over 3 months in patients (aged 6–17 years) with ADHD under routine care. Assessments were carried out at baseline (Visit 1), after 1–3 weeks (Visit 2) and 6–12 weeks (Visit 3) after first use of once-daily modified-release MPH. Change in ADHD symptoms, as rated by parents and teachers, was examined post hoc in patients of the intent-to-treat-population (N = 822), using growth-mixture modelling to detect response trajectory groups after switching medication. Age, MPH dose at Visit 1 before medication switch, prescribed once-daily modified-release MPH dose at Visits 1 and 2, conduct problems and emotional symptoms were considered predictors of response subgroups.

Results

Assessing formal statistical criteria and usefulness of the models, a 4-class solution best fitted the data: after switching medication two response groups with severe symptoms at study start and subsequent substantial treatment effects, and two showing no or comparatively little treatment effect, one of which had severe and the other less severe symptoms at study start. Patient age, conduct problems and MPH dose at Visit 1 were predictors of inclusion in subgroups.

Conclusions

Older children and children with few conduct problems were more likely to be members of a patient cluster with fewer symptoms at study start. Children with a low MPH dose before medication switch had a higher chance of being in the patient cluster with a strong treatment response after switching medication. The current analyses should assist in identifying children likely to achieve a favourable treatment course with MPH and, additionally, those who are in need of alternative treatment options.
Appendix
Available only for authorised users
Literature
1.
Faraone SV, Buitelaar J: Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010, 19: 353-364.CrossRefPubMed
2.
Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM: Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev. 2008, 28: 783-800. 10.1016/j.cpr.2007.10.007.CrossRefPubMed
3.
Connor DF, Steeber J, McBurnett K: A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr. 2010, 31: 427-440. 10.1097/DBP.0b013e3181e121bd.CrossRefPubMed
4.
Sinzig J, Döpfner M, Lehmkuhl G, German Methylphenidate Study Group: Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2007, 17: 421-432. 10.1089/cap.2007.0011.CrossRefPubMed
5.
Abikoff H, Hechtman L, Klein RG, Gallagher R, Fleiss K, Etcovitch J, Cousins L, Greenfield B, Martin D, Pollack S: Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004, 43: 820-829. 10.1097/01.chi.0000128797.91601.1a.CrossRefPubMed
6.
Wender PH, Reimherr FW, Marchant BK, Sanford ME, Czajkowski LA, Tomb DA: A one year trial of methylphenidate in the treatment of ADHD. J Atten Disord. 2011, 15: 36-45. 10.1177/1087054709356188.CrossRefPubMed
7.
Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Döpfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E: European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011, 20: 17-37. 10.1007/s00787-010-0140-6.CrossRefPubMed
8.
9.
Pliszka S: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007, 46: 894-921.CrossRefPubMed
10.
Taylor E, Döpfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A: European clinical guidelines for hyperkinetic disorder – first upgrade. Eur Child Adolesc Psychiatry. 2004, 13 (Suppl 1): i7-i30.PubMed
11.
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management: ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011, 128: 1007-1022.CrossRef
12.
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D: Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008, 165: 721-730. 10.1176/appi.ajp.2007.05091676.CrossRefPubMed
13.
Coghill D: What does it mean? Looking beyond group differences in clinical research. Eur Child Adolesc Psychiatry. 2011, 20: 537-539. 10.1007/s00787-011-0222-0.CrossRefPubMed
14.
Kazdin AE: Evidence-based treatment research: advances, limitations, and next steps. Am Psychol. 2011, 66: 685-698.CrossRefPubMed
15.
Ghuman JK, Riddle MA, Vitiello B, Greenhill LL, Chuang SZ, Wigal SB, Kollins SH, Abikoff HB, McCracken JT, Kastelic E, Scharko AM, McGough JJ, Murray DW, Evans L, Swanson JM, Wigal T, Posner K, Cunningham C, Davies M, Skrobala AM: Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol. 2007, 17: 563-580. 10.1089/cap.2007.0071.CrossRefPubMed
16.
17.
Vermunt JK: Longitudinal research using mixture models. Longitudinal research with latent variables. Edited by: van Montfort K, Oud JHL, Satorra A. 2010, Heidelberg: Springer, 119-152.CrossRef
18.
Lubke GH, Muthén B: Investigating population heterogeneity with factor mixture models. Psychol Methods. 2005, 10: 21-39.CrossRefPubMed
19.
Nagin DS, Odgers CL: Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010, 6: 109-138. 10.1146/annurev.clinpsy.121208.131413.CrossRefPubMed
20.
Sonuga-Barke EJ, Van Lier P, Swanson JM, Coghill D, Wigal S, Vandenberghe M, Hatch S: Heterogeneity in the pharmacodynamics of two long-acting methylphenidate formulations for children with attention deficit/hyperactivity disorder: a growth mixture modelling analysis. Eur Child Adolesc Psychiatry. 2008, 17: 245-254.CrossRefPubMed
21.
Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ: A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics. 2004, 113: e206-e216. 10.1542/peds.113.3.e206.CrossRefPubMed
22.
Swanson JM, Hinshaw SP, Arnold LE, Gibbons RD, Marcus S, Hur K, Jensen PS, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Pelham WE, Wells KC, Conners CK, March JS, Elliott GR, Epstein JN, Hoagwood K, Hoza B, Molina BS, Newcorn JH, Severe JB, Wigal T: Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses. J Am Acad Child Adolesc Psychiatry. 2007, 46: 1003-1014. 10.1097/CHI.0b013e3180686d63.CrossRefPubMed
23.
MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999, 56: 1073-1086.CrossRef
24.
Daughton JM, Kratochvil CJ: Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry. 2009, 48: 240-248. 10.1097/CHI.0b013e318197748f.CrossRefPubMed
25.
Ermer JC, Adeyi BA, Pucci ML: Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder. CNS Drugs. 2010, 24: 1009-1025. 10.2165/11539410-000000000-00000.CrossRefPubMed
26.
Wolraich ML, Doffing MA: Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs. 2004, 18: 243-250. 10.2165/00023210-200418040-00004.CrossRefPubMed
27.
Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E: Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006, 15: 476-495. 10.1007/s00787-006-0549-0.CrossRefPubMed
28.
Hosenbocus S, Chahal R: A review of long-acting medications for ADHD in Canada. J Can Acad Child Adolesc Psychiatry. 2009, 18: 331-339.PubMedPubMedCentral
29.
Faraone SV: Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. Proc Natl Acad Sci USA. 2009, 34: 678-694.
30.
31.
Anderson VR, Keating GM: Methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder. Paediatr Drugs. 2006, 8: 319-333. 10.2165/00148581-200608050-00005.CrossRefPubMed
32.
Döpfner M, Görtz-Dorten A, Breuer D, Rothenberger A: An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. Eur Child Adolesc Psychiatry. 2011, 20: S243-S255. 10.1007/s00787-011-0202-4.CrossRefPubMed
33.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. 2000, Washington: APACrossRef
34.
World Health Organization: International Classification of Diseases (ICD-10). 1992, Geneva: WHO
35.
36.
The European Parliament and the Council of the European Union: Directive. 2001, http://​www.​eortc.​be/​services/​doc/​clinical-eu-directive-04-april-01.​pdf, /20/EC of the European Parliament and the Council of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Humn Use,
37.
Döpfner M, Görtz-Dorten A, Lehmkuhl G: DISYPS-II: Diagnostik-System für psychische Störungen im Kindes- und Jugendalter nach ICD-10 und DSM-IV. 2008, Bern: Hans Huber
38.
Goodman R: The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry. 1997, 38: 581-586. 10.1111/j.1469-7610.1997.tb01545.x.CrossRefPubMed
39.
Muthén B, Shedden K: Finite mixture modeling with mixture outcomes using the EM algorithm. Biometrics. 1999, 55: 463-469. 10.1111/j.0006-341X.1999.00463.x.CrossRefPubMed
40.
Muthén B: Latent variable analysis: growth mixture modeling and related techniques for longitudinal data. Handbook of quantitative methodology for the social sciences. Edited by: Kaplan D. 2004, Newbury Park: Sage, 345-368.
41.
Singer JD, Willett JB: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. 2003, New York: Oxford University PressCrossRef
42.
Muthén B: Mplus Technical Appendices. 2004, Los Angeles: Muthén & Muthén
43.
Roeder K, Lynch KG, Nagin DS: Modeling uncertainty in latent class membership: a case study in criminology. J Am Stat Assoc. 1999, 94: 766-776. 10.1080/01621459.1999.10474179.CrossRef
44.
Arbuckle JL: Full information estimation in the presence of incomplete data. Advanced structural equation modelling: issues and techniques. Edited by: Marcoulides GA, Schumacker RE. 1996, Mahwah: Lawrence Erlbaum, 243-277.
45.
Raykov T: Analysis of longitudinal studies with missing data using covariance structure modeling with full-information maximum likelihood. Struct Equation Model. 2005, 12: 493-505. 10.1207/s15328007sem1203_8.CrossRef
46.
Schwarz G: Estimating the dimension of a model. Ann Stat. 1978, 6: 461-464. 10.1214/aos/1176344136.CrossRef
47.
Muthén B, Muthén L: Mplus (Version 6.12) [Computer Software]. 2011, Los Angeles: Muthén & Muthén
48.
Faraone SV, Biederman J, Mick E: The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006, 36: 159-165.CrossRefPubMed
49.
Waschbusch DA: A meta-analytic examination of comorbid hyperactive-impulsive-attention problems and conduct problems. Psychol Bull. 2002, 128: 118-150.CrossRefPubMed
50.
Castells X, Ramos-Quiroga JA, Rigau D, Bosch R, Nogueira M, Vidal X, Casas M: Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs. 2011, 25: 157-169. 10.2165/11539440-000000000-00000.CrossRefPubMed
51.
Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH: A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003, 112: e404-10.1542/peds.112.5.e404.CrossRefPubMed
52.
Pelham WE, Fabiano GA: Evidence-based psychosocial treatments for attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol. 2008, 37: 184-214. 10.1080/15374410701818681.CrossRefPubMed
53.
Young S, Amarasinghe JM: Practitioner review: non-pharmacological treatments for ADHD: a lifespan approach. J Child Psychol Psychiatry. 2010, 51: 116-133. 10.1111/j.1469-7610.2009.02191.x.CrossRefPubMed
54.
Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M: Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med. 1987, 17: 121-143. 10.1017/S0033291700013039.CrossRefPubMed
55.
MTA Cooperative Group: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry. 1999, 56: 1088-1096.CrossRef
56.
Owens EB, Hinshaw SP, Kraemer HC, Arnold LE, Abikoff HB, Cantwell DP, Conners CK, Elliott G, Greenhill LL, Hechtman L, Hoza B, Jensen PS, March JS, Newcorn JH, Pelham WE, Severe JB, Swanson JM, Vitiello B, Wells KC, Wigal T: Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol. 2003, 71: 540-552.CrossRefPubMed
57.
Tannock R: ADHD with anxiety disorders. ADHD comorbidities: Handbook for ADHD complications in children and adults. Edited by: Brown TE. 2009, Arlington: American Psychiatric Publishing, 131-155.
58.
Döpfner M, Breuer D, Walter D, Rothenberger A: An observational study of once-daily modified-release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality of life outcomes. Eur Child Adolesc Psych. 2011, 20: S277-S288.CrossRef
59.
Evidence-Based Medicine Working Group: Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA. 1992, 268: 2420-2425. 10.1001/jama.1992.03490170092032.CrossRef
60.
Montori VM, Guyatt GH: Progress in evidence-based medicine. JAMA. 2008, 300: 1814-1816. 10.1001/jama.300.15.1814.CrossRefPubMed
61.
Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D: Current methods of the US preventive services task force: a review of the process. Am J Prev Med. 2001, 20: 21-35.CrossRefPubMed
62.
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams JW, Zaza S: Grading quality of evidence and strength of recommendations. BMJ. 2004, 328: 1490-CrossRefPubMed
63.
Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000, 342: 1887-1892. 10.1056/NEJM200006223422507.CrossRefPubMedPubMedCentral
64.
65.
Collins LM: Analysis of longitudinal data: the integration of theoretical model, temporal design, and statistical model. Annu Rev Psychol. 2006, 57: 505-528. 10.1146/annurev.psych.57.102904.190146.CrossRefPubMed
Metadata
Title
An observational study of response heterogeneity in children with attention deficit hyperactivity disorder following treatment switch to modified-release methylphenidate
Authors
Christopher Hautmann
Aribert Rothenberger
Manfred Döpfner
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2013
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-13-219

Other articles of this Issue 1/2013

BMC Psychiatry 1/2013 Go to the issue

Study protocol

Multimodal neuroimaging of frontal white matter microstructure in early phase schizophrenia: the impact of early adolescent cannabis use

Research article

The Peritraumatic Behavior Questionnaire: development and initial validation of a new measure for combat-related peritraumatic reactions

Research article

The association between social relationships and self-harm: a case–control study in Taiwan

Study protocol

Effectiveness and underlying mechanisms of a group-based cognitive behavioural therapy-based indicative prevention program for children with elevated anxiety levels

Research article

Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis

Research article

Perception of depressive symptoms by the Sardinian public: results of a population study